Gerald L. Andriole Jr., MDRoyce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri.
Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.
Dr. Andriole has over 30 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 300 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, the Prostate Cancer Early Detection Panel of the National Comprehensive Cancer Network, American Surgical Association and the American Association of Genitourinary Surgeons among other societies.
Recent Contributions to PracticeUpdate:
- Association of Baseline PSA Level With Long-Term Diagnosis of Clinically Significant Prostate Cancer in Men Aged 55–60
- 10-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men With Localized Prostate Cancer
- Decision Aids for Prostate Cancer Screening Choice
- Population-Based Outcomes of Men With a Single Negative Prostate Biopsy
- Long-Term Prostate Cancer Risk of Finasteride
- Low-Intensity PSA-Based Screening Intervention Does Not Impact Prostate Cancer Mortality
- AUA Policy Statement on the Use of MRI in the Diagnosis, Staging, and Management of Prostate Cancer
- Radical Prostatectomy in Men With Oligometastatic Prostate Cancer
- Negative Multiparametric Prostate MRI Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
- The Controversy Over PSA Testing Stumbles On